`
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`______________________
`
`MYLAN LABORATORIES LTD.
`PETITIONER,
`
`v.
`
`JANSSEN PHARMACEUTICA NV
`PATENT OWNER.
`
`U.S. Patent No. 9,439,906 to Vermeulen et al.
`Issue Date: September 13, 2016
`
`Title: Dosing Regimen Associated with Long
`Acting Injectable Paliperidone Esters
`
`Inter Partes Review No.: IPR2020-00440
`
`PETITIONER MYLAN LABORATORIES LTD FIRST UPDATED
`MANDATORY NOTICE UNDER 37 C.F.R. 42
`
`
`
`Pursuant to 37 C.F.R. §42.8(a)(3) and §42.8(b)(1), Petitioner Mylan
`
`Laboratories Ltd. (“Mylan”) hereby updates its mandatory notices as set forth
`
`below. No other changes to any of the previously identified information under
`
`37 C.F.R. §42.8 are being made pursuant to this Notice.
`
`Each Real Party in Interest (37 C.F.R. § 42.8(b)(1))
`
`On November 16, 2020, Viatris Inc. replaced Mylan N.V. as the parent
`
`company of all entities that were previously subsidiaries of Mylan N.V.
`
`Accordingly, Mylan identifies Viatris Inc. as a real party-in-interest.
`
`Dated: December 12, 2020
`
`Respectfully submitted,
`
`Katten Muchin Rosenman LLP
`
`/Jitendra Malik/
`Jitendra Malik (Reg. No. 55,823)
`
`Lead Counsel for Petitioner
`
`i
`
`
`
`CERTIFICATION OF SERVICE ON PATENT OWNER
`Pursuant to 37 C.F.R. §§ 42.6(e), 42.8(b)(4), and 42.105, the undersigned
`
`certifies that on December 2, 2020, a complete copy of the foregoing Paper were
`
`served via email to all other interested parties at:
`
`bmullin@pbwt.com
`
`acohen@pbwt.com
`
`jcho@pbwt.com
`
`rmunoz@akingump.com
`
`Dated: December 2, 2020
`
`Respectfully submitted,
`
`Katten Muchin Rosenman LLP
`
`/Jitendra Malik/
`Jitendra Malik (Reg. No. 55,823)
`
`Lead Counsel for Petitioner
`
`